Navigation Links
Global CEO Initiative on Alzheimer's Disease (CEOi) Commits Industry to Innovation and Leadership in the Global Fight Against Alzheimer's and Dementia
Date:5/1/2013

LOS ANGELES, May 1, 2013 /PRNewswire-USNewswire/ -- The Global CEO Initiative on Alzheimer's Disease (CEOi), a new business consortium leading the fight against Alzheimer's, today announced its commitment to a new global framework to combat Alzheimer's disease.  The CEOi's goal is to create a clear pathway to diagnose, prevent and treat Alzheimer's by 2025, aligned with global and national plans to address Alzheimer's and other dementias.

In line with this goal, this morning's panel at the 2013 Milken Institute Global Conference will highlight the critical positive contribution to global economic growth and sovereign operating budgets with the prevention of Alzheimer's.  The panel, titled "Stopping Alzheimer's: Personal, Economic and Policy Imperatives," will feature experts with diverse backgrounds across health, technology, drug development, foreign policy and advocacy, who will share key insights and perspectives about the impacts of Alzheimer's on patients and caregivers, the global healthcare system, foreign policy, and global growth and competitiveness.

"Alzheimer's disease is an unprecedented global health burden with devastating social and financial effects on individuals, families and communities, but the immense global economic and fiscal consequences of the disease have only recently emerged as a topic of global conversation," said George Vradenburg , Convener of the CEOi.  "Global leadership and collaboration across business and government are essential to drive coordinated action, promote rapid innovation and spur the focus needed to achieve a means of prevention and effective diagnosis, treatment and care for Alzheimer's and dementia."

Speakers during today's panel, which will take place at 8:30 a.m. at the Beverly Hilton, include:

  • Neil de Crescenzo , Senior Vice President and General Manager of Health Sciences, Oracle
  • Robert Hormats , Under Secretary, Economic Growth, Energy, and the Environment, U.S. Department of State
  • Sue Siegel , CEO, healthymagination, GE
  • George Vradenburg , Convener, The Global CEO Initiative on Alzheimer's Disease
  • Anne Whitaker , President, North America Pharmaceuticals, Sanofi
  • Cecilia Arradaza , Director, Communications and Policy, FasterCures (moderator)

"Alzheimer's is one of the seminal public health issues of our time; the fiscal and social implications cannot be ignored," said Anne Whitaker , President, North America Pharmaceuticals, Sanofi. "From a health perspective and a business perspective, our only option is to pursue a comprehensive framework that includes partnerships, research investments, business models and policy changes to turn this pending crisis into opportunity."

Alzheimer's and dementia is a global public health priority that requires a global solution.  According to the World Health Organization and the Alzheimer's Disease International 2012 Dementia Report, in 2010, there were approximately 36 million people worldwide suffering from dementia – most diagnosed over the age of 60 – and that number will spike to 115 million by 2050.  Further, the total worldwide costs of dementia, including Alzheimer's disease, were estimated to exceed $600 billion, which is equivalent to one percent of global gross domestic product (GDP).  Combined with a lack of treatment options and the aging of the global population, both prevalence and cost will skyrocket without proper attention and investment.   

"CEOi intends to utilize our collective expertise across the health, diagnostic, medical, financial services and technology sectors to drive new solutions to support Alzheimer's patients and caregivers," said Sue Siegel , CEO of healthymagination, GE.  "Through our expertise, innovation and collaboration, the CEOi will build upon national commitments and plans in the U.S. and across the globe to place Alzheimer's at the forefront of critical research, care, awareness and funding priorities in order to stop this global threat by 2025."

The founding members of the CEOi include biopharmaceutical and healthcare companies AC Immune, Eli Lilly and Company, Janssen Research & Development, LLC, Merck, Pfizer, Inc. Sanofi and Nestle Health Science; financial services provider Bank of America Merrill Lynch; healthcare solutions company GE Healthcare; and Banner Health, a large multi-state, not-for-profit healthcare system.

Through collaboration with governments, non-governmental organizations and academia, the CEOi will build proactive strategies to meet four goals aimed at stopping Alzheimer's disease by 2025, including:

  1. Develop a global Alzheimer's framework to prevent and effectively treat Alzheimer's by 2025, with specific, milestone-driven actions to increase global research resources as well as reduce the time, cost and risk in developing Alzheimer's therapies;
  2. Develop a comprehensive global Alzheimer's agenda to align basic and translational  academic and industrial research and drug development;
  3. Articulate the fiscal and economic case for global action and new investment models and innovations in treatment, care and care delivery; and
  4. Enhance public engagement to emphasize the value of early detection and diagnosis and to increase awareness of the economic, social and personal benefits of a public commitment to stopping Alzheimer's disease.

The Global CEO Initiative on Alzheimer's Disease (CEOi) is an organization of private-sector leaders who have joined together to provide business leadership in the fight against Alzheimer's. The CEO Initiative seeks to partner with public leaders to transform the disease from a social, health, and economic crisis into an opportunity for healthy aging and innovation in research and care. The CEO Initiative believes that, during this era of aging populations, it will take visionary, coordinated, goal-oriented leadership of public and private leaders working together to solve our greatest challenges. Learn more at: www.ceoalzheimersinitiative.org.


'/>"/>
SOURCE The Global CEO Initiative on Alzheimer’s Disease (CEOi)
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
2. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
3. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
4. StemCyte Adds World Class Talent to its North America and Global Operations
5. Sequenom Named to NASDAQ Global Select Market
6. Synthetic Biology: Emerging Global Markets
7. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
8. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
11. Accuray Surpasses 600 Installations Globally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting ... a professor in Harvard University’s Departments of Physics and Astronomy, has been selected for ... of the winning team for the 2015 Breakthrough Prize in Fundamental physics for the ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):